

## Breakfast with the Investigators: New Agents and Strategies in the Management of Ovarian Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Olaparib is FDA approved as maintenance therapy after response to platinum-based therapy in patients with BRCA mutation-positive disease only.
  - True
  - False
- In the Phase III ENGOT-OV16/NOVA trial evaluating maintenance therapy with niraparib versus placebo for patients with platinum-sensitive, recurrent ovarian cancer, treatment with niraparib resulted in a significant improvement in progression-free survival for patients with \_\_\_\_\_.
  - Germline BRCA mutations
  - No germline BRCA mutation, irrespective of homologous recombination deficiency (HRD) status
  - Both a and b
- The pivotal study that led to the FDA approval of rucaparib as maintenance therapy for patients with ovarian cancer who have responded to platinum-based chemotherapy is \_\_\_\_\_.
  - SOLO-2
  - ARIEL2
  - ARIEL3
- The ongoing Phase III SOLO-1 trial is investigating olaparib maintenance monotherapy after first-line platinum-based chemotherapy for patients with \_\_\_\_\_ ovarian cancer.
  - BRCA mutation-positive
  - BRCA mutation-negative
  - Both a and b
- The single-arm Phase II QUADRA study demonstrated an objective response rate of 27.5% with niraparib for patients with ovarian cancer in which of the following settings?
  - Newly diagnosed disease
  - Relapsed disease after 2 or more lines of chemotherapy
  - Relapsed disease after 3 or more prior lines of chemotherapy
- The Phase II KEYNOTE-100 study is investigating the checkpoint inhibitor \_\_\_\_\_ for patients with advanced recurrent ovarian cancer.
  - Nivolumab
  - Atezolizumab
  - Pembrolizumab
- Side effects associated with the antibody-drug conjugate mirvetuximab soravtansine in the treatment of ovarian cancer include \_\_\_\_\_.
  - Diarrhea
  - Blurred vision
  - Nausea
  - Neuropathy
  - All of the above
- The Phase III FORWARD I study is comparing chemotherapy to \_\_\_\_\_ for patients with platinum-resistant advanced ovarian cancer that is folate receptor alpha-positive.
  - Pembrolizumab
  - Mirvetuximab soravtansine
  - Bevacizumab

Breakfast with the Investigators: New Agents and Strategies in the Management of Ovarian Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

9. The results of the Phase III ARIEL3 trial of rucaparib maintenance therapy after platinum-based chemotherapy for patients with platinum-sensitive high-grade ovarian cancer demonstrated a statistically significant improvement in progression-free survival with rucaparib versus placebo in which population of patients?
- a. Patients with BRCA mutation-positive tumors
  - b. Patients with HRD-positive disease
  - c. The intent-to-treat population
  - d. All of the above
10. Study 19, investigating maintenance olaparib after complete or partial response to platinum-based chemotherapy in patients with platinum-sensitive, recurrent ovarian cancer, reported a statistically significant improvement in overall survival for patients who received olaparib compared to placebo.
- a. True
  - b. False